Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03313778
Title	Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603)
Acronym	KEYNOTE-603
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	ModernaTX, Inc.
Indications	Advanced Solid Tumor bladder urothelial carcinoma colorectal cancer esophagus adenocarcinoma melanoma gastric adenocarcinoma endometrial cancer lung non-small cell carcinoma lung small cell carcinoma head and neck squamous cell carcinoma
Therapies	mRNA-4157 + Pembrolizumab mRNA-4157
Age Groups:	adult \| senior
Covered Countries	USA \| GBR \| AUS